Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.
586 articles
Showing 97–105 of 105 articles · Keyword: lipid nanoparticle Clear keyword
Da Ma
siRNA-based gene therapy is a promising biotechnology for treating cancer and other diseases, but safe and efficient delivery is essential. Nanoparticle-mediated delivery must overcome multiple biological barriers, and endosomal escape is a critical rate-limiting barrier: nanoparticles are typically internalised via…
Read the articleLopes Rm, Gaspar Mm, Pereira J, Eleuterio Cv, Carvalho M, Almeida Aj, Cruz Mem
Current leishmaniasis chemotherapy lacks options that combine high activity, low toxicity, and affordable cost. Oryzalin (ORZ), a dinitroaniline with in vitro antileishmanial activity, is limited by poor water solubility and low accumulation in diseased organs. Lipid-based nanocarriers may overcome these limitations…
Read the articleTorrecilla J, Rodríguez-Gascón A, Solinís Má, Del Pozo-Rodríguez A
Naked RNAi molecules are rapidly degraded by serum nucleases and cannot readily cross cell membranes because of their negative charge. Effective delivery systems are therefore required to exploit RNAi for antiviral therapy. Lipid nanoparticles (LNPs) are attractive because they are relatively safe, simple to produce…
Read the articleSlavomíra Doktorovová, Eliana B. Souto, Amélia Maria Silva
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were developed as alternative colloidal carriers with better stability and tolerability than polymeric nanoparticles. However, in vitro toxicity data were scattered across many cell lines, assays, exposure times, concentrations, and formulations…
Read the articleTam Yyc, Chen S, Cullis Pr
siRNA has broad therapeutic potential, but clinical translation is limited by rapid nuclease degradation, poor accumulation in target tissues, and inability to cross cell membranes to reach the cytoplasm. Lipid nanoparticles containing ionisable amino lipids are the leading systemic delivery system for siRNA, with…
Read the articleGan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, Liu J, Gan Y
Topical ocular drug delivery is limited by tear turnover, corneal and conjunctival barriers, efflux transporters, and poor water solubility of many drug candidates. Lipid-based nanocarriers may improve ocular bioavailability, prolong preocular residence, enhance corneal penetration, and provide controlled release…
Read the articleWei-Yun Sheng, Leaf Huang
The immune system can recognise and kill pre-cancer and cancer cells, but surviving tumour cells learn to escape immune surveillance after immunoselection. Cancer immunotherapy aims to overcome these escape mechanisms. Nanomedicine offers tools—nanodiagnostics and nanobiopharmaceuticals—to deliver antigens…
Read the articleLi W, Szoka Fc Jr
Systemic non-viral gene delivery is limited by rapid clearance, toxicity, and poor target-cell access. Cationic lipid–DNA lipoplexes are effective in vitro but perform poorly in vivo because they aggregate with serum proteins, are cleared by the reticuloendothelial system (RES), and accumulate mainly in lung and…
Read the articleAdi Mesika, Irina Grigoreva, Muriel Zohar, Ziv Reich
Transfection efficiency of nonviral gene delivery systems remains unacceptably low, largely due to the inability of plasmid DNA to effectively translocate through the nuclear pore complexes (NPCs). While substantial progress has been made in transcriptionally regulated vectors, control over nuclear targeting is…
Read the articleWe co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
